Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Curasan AG       


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

curasan : still on track despite of weaker second quarter

share with twitter share with LinkedIn share with facebook
share via e-mail
08/22/2019 | 01:55am EDT

DGAP-News: curasan AG / Key word(s): Half Year Results
curasan AG still on track despite of weaker second quarter

22.08.2019 / 07:51
The issuer is solely responsible for the content of this announcement.


- Net sales declined with EUR 3.1 million by 7.6 percent in the first half year

- Positive signals from the Middle East

- Special effects press EBITDA to EUR -1.5 million

Kleinostheim, 22 August 2019 - curasan AG, Germany, (ISIN DE000A2YPGM4), a leading specialist for medical products in the field of orthobiologics, has published its financial figures for the first half year 2019 today. Mostly due to supply shortages, sales showed a declining trend. The company was able to react and cut short-term spending on marketing and sales. However, special items had a negative impact on earnings to an increased extent.

In the first half year 2019 net sales declined by 7.6 percent to EUR 3.1 million. Positive signals were again generated in the Middle East region, where demand picked up significantly, as in the first quarter. Sales in Europe increased by
6.7% compared to the previous year. Overall, however, this was not enough to offset the sales that had been postponed to the third quarter.

Earnings before interest, taxes, depreciation and amortization (EBITDA) were disproportionately lower at EUR -1.5 million and 30.7 percent below previous year. Despite significantly lower marketing and sales expenses and strict cost management, it was not possible to achieve the previous year's result. A key factor in this was special expenses for the necessary Extraordinary General Meeting as well as for the preparation and issuance of a convertible bond which reduced the result by a total of around EUR 0.2 million.

The relevant key figures for the first half year 2019 are as follows:

IFRS (in TEUR) H1 2019 H1 2018 Deviation
Net group sales 3,142 3,399 -7.6%
EBITDA -1,528 -1,169 -30.7%
EBIT -1,860 -1,465 -27.0%
Net result -1,890 -1,504 -25.7%
Equity (vs. ultimo 2018) 5,663 7,521 -24.7%
Cash (vs. ultimo 2018) -148 -108 -37.0%

Against the backdrop of the implemented cost-cutting measures and the measures taken in receivables management, cash and cash equivalents decreased by only EUR 40 thousand to EUR -148 thousand. For the further financing of business operations, the company issued a convertible bond in May, which leads to an improved liquidity situation in the third quarter 2019. After the end of the reporting period curasan AG, the company also carried out a capital increase with subscription rights for the shareholders, through which the company received approximately EUR 3.1 million.

The Management Board continues to maintain the outlook for revenue and earnings development for 2019.

The audited interim report for the first half of 2019 is available for download on the company's website at the following link:

Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

22.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 861483

End of News DGAP News Service

861483  22.08.2019 


© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CURASAN AG
10/01CURASAN : launches product for the treatment of the spinal facet syndrome
09/12CURASAN : New CEO at curasan AG
09/12CURASAN : Torben Sorensen new CEO at curasan AG
09/12CURASAN : Torben Sorensen new CEO at curasan AG
09/12CURASAN : New CEO at curasan AG
09/10CURASAN AG : Release according to Article 40, Section 1 of the WpHG [the German ..
08/22CURASAN : still on track despite of weaker second quarter
08/22CURASAN : still on track despite of weaker second quarter
07/03CURASAN : takes over dental company with innovative technology
More news
Torben Sorensen Chief Executive Officer
Detlef Wilke Chairman-Supervisory Board
Fabian Peters Technical Director
Christine Böhm Chief Medical Officer
Isabella de Krassny Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED32.07%74 822
BIOGEN INC.-24.98%41 641
GRIFOLS19.00%18 040